兹卡病毒药物市场规模、份额及成长分析（按疫苗类型、按检测类型、按最终用户、按地区）- 产业预测（2025-2032）

2023 年全球兹卡病毒治疗市场规模为 20 亿美元，预计将从 2024 年的 22.7 亿美元成长到 2032 年的 63 亿美元，预测期间（2025-2032 年）的复合年增长率为 13.6%。

由于感染率上升、药物研发持续进行以及预防和疫苗接种意识不断增强，全球兹卡病毒药物市场正在经历显着增长。兹卡主要透过蚊子传播，会导致严重的出生缺陷和神经系统问题，尤其是在热带地区，这进一步推动了需求。 mRNA 技术和数位监控工具等技术进步正在加速疫苗的开发和安全性。例如，Moderna 的创新 mRNA-1893 疫苗目前正在进行临床试验，旨在不使用活株有效对抗病毒。此外，人工智慧、机器学习和区块链技术的整合正在提高疫苗生产和分发的效率。这些创新透过建立信任、推广有效治疗和教育大众，重建了对兹卡药物治疗的需求。

目录

介绍

• 分析目的
• 市场覆盖
• 定义

分析方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与约束

执行摘要

• 市场概况与展望
• 供需趋势分析
• 按细分市场进行机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场观察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场魅力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

全球兹卡病毒药物市场规模及各疫苗类型复合年增长率（2025-2032）

• 市场概览
• 灭活病毒疫苗
• 减毒活疫苗
• DNA疫苗
• mRNA疫苗

全球兹卡病毒药物市场规模及复合年增长率（按检测类型划分）（2025-2032 年）

• 市场概览
• 分子检测
• 血清学检测

全球兹卡病毒药物市场规模及最终用户复合年增长率（2025-2032）

• 市场概览
• 医院和诊所
• 研究机构

全球兹卡病毒药物市场规模及按分销管道分類的复合年增长率（2025-2032）

• 市场概览
• 医院药房
• 零售药局
• 网路药局

全球兹卡病毒治疗市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争格局

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要企业采取的策略
• 近期市场趋势
• 主要企业市场占有率（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Moderna Inc.（USA）
• Valneva SE（France）
• Inovio Pharmaceuticals, Inc.（USA）
• Emergent BioSolutions Inc.（USA）
• Novavax, Inc.（USA）
• Johnson & Johnson（USA）
• Pfizer Inc.（USA）
• Bharat Biotech International Ltd.（India）
• GeoVax Labs, Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• GlaxoSmithKline plc（GSK）（UK）
• BioCryst Pharmaceuticals, Inc.（USA）
• Zydus Cadila（India）
• GeneOne Life Science Inc.（South Korea）
• Kimer Med（Spain）
• BioVaxys Technology Corporation（Canada）
• Creative Diagnostics（USA）
• Indian Immunologicals Limited（India）
• Sanofi Pasteur（France）

结论和建议

Global Zika Virus Therapeutics Market size was valued at USD 2.0 billion in 2023 and is poised to grow from USD 2.27 billion in 2024 to USD 6.3 billion by 2032, growing at a CAGR of 13.6% during the forecast period (2025-2032).

The global Zika virus therapeutics market is witnessing significant growth due to rising infection rates, ongoing pharmaceutical research and development, and heightened awareness surrounding prevention and vaccination. Primarily transmitted by mosquitoes, Zika causes severe birth defects and neurological issues, particularly in tropical regions, further driving demand. Technological advancements, such as mRNA technology and digital monitoring tools, have accelerated the development and safety of vaccines. For example, Moderna's innovative mRNA-1893 vaccine is currently in clinical trials, aiming to efficiently combat the virus without utilizing live strains. Additionally, the integration of AI, machine learning, and blockchain technology is enhancing vaccine production and distribution efficiency. These innovations are building trust, promoting effective treatments, and educating the public, reshaping demand in the Zika therapeutics landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Zika Virus Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Zika Virus Therapeutics Market Segments Analysis

Global Zika Virus Therapeutics Market is segmented by Vaccine Type, Test Type, End User, Distribution Channel and region. Based on Vaccine Type, the market is segmented into Inactivated Virus Vaccine, Live Attenuated Vaccine, DNA Vaccine and mRNA Vaccine. Based on Test Type, the market is segmented into Molecular Test and Serological Test. Based on End User, the market is segmented into Hospitals and Clinics and Research Institutes. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Zika Virus Therapeutics Market

The rising incidence of Zika virus, especially in tropical and subtropical areas, is driving the growth of the global Zika virus therapeutics market. Factors such as increased global travel, climate change, urbanization, and the expanding mosquito population are intensifying the need for effective prevention and treatment measures. In response to this growing threat, governments and international health organizations are making substantial investments in Zika virus prevention strategies, further boosting the demand for therapeutics. This surge in investment and awareness is critical in addressing the escalating challenges posed by the Zika virus on public health.

Restraints in the Global Zika Virus Therapeutics Market

The global Zika virus therapeutics market faces significant restraints primarily due to the high costs associated with the development process. These expenses arise from the intricate nature of research and development, along with the necessity for multiple clinical trials prior to vaccine introduction. Additionally, varying acceptance criteria set by regulatory bodies such as the ICMRA in India, the FDA in the United States, and the European Union necessitate ongoing research and heavier investments. Furthermore, many vaccines demand cold storage and efficient cold chain logistics, which subsequently elevate operational costs, thereby posing additional challenges in bringing effective therapeutics to market.

Market Trends of the Global Zika Virus Therapeutics Market

The Global Zika Virus Therapeutics market is witnessing a significant trend towards the advancement of vaccine technologies, particularly with the emergence of mRNA and DNA platforms. These innovative technologies enable faster and more efficient vaccine development, allowing companies to respond swiftly to outbreaks. The accelerated approval process by regulatory bodies, coupled with the growing endorsement from medical organizations, fosters greater acceptance and confidence in these vaccines among the public. As global health agencies prioritize Zika virus prevention, the market is poised for robust growth, driven by enhanced research activities, collaborative efforts, and increased investment in novel therapeutic solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Zika Virus Therapeutics Market Size by Vaccine Type & CAGR (2025-2032)

• Market Overview
• Inactivated Virus Vaccine
• Live Attenuated Vaccine
• DNA Vaccine
• mRNA Vaccine

Global Zika Virus Therapeutics Market Size by Test Type & CAGR (2025-2032)

• Market Overview
• Molecular Test
• Serological Test

Global Zika Virus Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals and Clinics
• Research Institutes

Global Zika Virus Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Zika Virus Therapeutics Market Size & CAGR (2025-2032)

• North America (Vaccine Type, Test Type, End User, Distribution Channel)
  • US
  • Canada
• Europe (Vaccine Type, Test Type, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Vaccine Type, Test Type, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Vaccine Type, Test Type, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, Test Type, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Moderna Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valneva SE (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inovio Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novavax, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech International Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeoVax Labs, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioCryst Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneOne Life Science Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kimer Med (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioVaxys Technology Corporation (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Diagnostics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Indian Immunologicals Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi Pasteur (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations